Publications by authors named "C Teijon-Lumbreras"
Article Synopsis
- * The review focuses on the experience of developing a virtual control center for COVID-19 patients in Spain, showcasing how CDSS allowed for real-time monitoring and improved personalized medical care during the pandemic.
- * While CDSS can enhance patient care quality and increase healthcare efficiency, challenges remain, such as the need for training medical professionals to use the systems effectively and maintaining updated software.
Background: This study aimed to describe documented infections associated with postinfusion fever after CAR T-cell therapy and to evaluate daily changes in vital signs, laboratory results, and the National Early Warning Score (NEWS) in patients with and without confirmed bacterial infections following fever onset, with the objective of assisting in antibiotic stewardship.
Methods: This was a retrospective, observational study including all consecutive adult patients who received CAR T-cell therapy. Documented infection in the first fever episode after infusion, and clinical and analytic trend comparison of patients with bacterial documented infections and those without documented infections, are described.
Objectives: To describe the management of haematological patients experiencing prolonged SARS-CoV-2 viral shedding, as the optimal management strategy for this condition remains undetermined.
Methods: We conducted a retrospective evaluation of our prospectively followed cohort of haematological patients treated with remdesivir for more than 10 days. Starting January 2023, upon COVID-19 diagnosis, the treatment strategy was based on symptoms and PCR cycle threshold (Ct) as follows: (i) when Ct was 25 or less or if the patient had symptoms, a course of remdesivir for at least 10 days, nirmatrelvir/ritonavir for 5 days (whenever possible) and convalescent plasma was administered; and (ii) when the patient was asymptomatic and had a PCR Ct of more than 25, when possible, a course of 5 days of nirmatrelvir/ritonavir was administered.
Article Synopsis
- Researchers studied the rise of azole-resistant invasive aspergillosis in hematology patients in a Spanish hospital over the last 4 months, identifying 4 cases total, with 3 being azole-resistant.
- The diagnostic methods included fungal culture, antifungal susceptibility testing, and real-time PCR for detecting both Aspergillus species and azole resistance mutations like TR34/L98H.
- Findings showed that all azole-resistant cases had significant hematologic conditions and risk factors, indicating a pressing need for better monitoring and development of new antifungal treatments.
Introduction: The impact of remdesivir on mortality in patients with COVID-19 is still controversial. We aimed to identify clinical phenotype clusters of COVID-19 hospitalized patients with highest benefit from remdesivir use and validate these findings in an external cohort.
Methods: We included consecutive patients hospitalized between February 2020 and February 2021 for COVID-19.